SABS
NASDAQ
$3.64
SAB Biotherapeutics Inc (SABS)
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. The company is headquartered in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $11.18 (+207.14%)
Market Cap
$274M
P/E Ratio
14.14
Free Cash Flow Yield
-19.39%
Beta (5Y)
0.83
Price Chart
Valuation
Market Cap$274M
P/E14.14
P/S2.96
P/B1.21
Profitability
Gross Profit (TTM)-$39M
EBITDA-$55M
EPS$0.26
Financial Health
Free Cash Flow Yield-19.39%
Growth & Risk
Beta (5Y)0.83
Sharpe Ratio0.60